Antibody · 폐암 (NSCLC)

AntibodystaleAssistance Publique Hopitaux De…Phase 2

MEDI9447 (Oleclumab, Oleclumab (MEDI9447))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2

AntibodyBiologicstaleGuangzhou Anjie Biomedical Tech…Phase 2

PD-1 mAb (PD-1 mAb)

Lung Neoplasm Malignant; Non-small Cell Lung Cancer · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4

AntibodystaleAmgenPhase 2

ABX-EGF (Panitumumab, Panitumumab (ABX-EGF))

Colorectal Cancer; Non-Small Cell Lung Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+3

#AdvancedorMetastaticNon-squamous#Antibody#Phase3#항체#면역항체+2

EU (Pembrolizumab, Pembrolizumab (EU))

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer · Advanced or Metastatic Non-squamous Non-

#AdvancedorMetastaticNon-squamous#Antibody#Phase3#항체#면역항체+2

US (Pembrolizumab, Pembrolizumab (US))

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer · Advanced or Metastatic Non-squamous Non-

#LungNeoplasmMalignant#Antibody#Phase2#항체#면역항체+2

adjuvant (Pembrolizumab, Pembrolizumab (adjuvant))

Lung Neoplasm Malignant · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Phase2#항체#면역항체+2

neoadjuvant (Pembrolizumab, Pembrolizumab (neoadjuvant))

Lung Neoplasm Malignant · Lung Neoplasm Malignant

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+2

Investigator's choice (Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice))

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

임상시험 1상태 DISCONTINUED

#NonsquamousNon-smallCellLungCanc#Antibody#Phase2#항체#면역항체+2

pembrolizumab (Keytruda, Pembrolizumab + Carboplatin + Pemetrexed)

Nonsquamous Non-small Cell Lung Cancer · Nonsquamous Non-small Cell Lung Cancer

효능 ORR 84%임상시험 1상태 DISCONTINUED

#GutMicrobiota#Antibody#Phase2#항체#면역항체+3

pembrolizumab (Keytruda, Pembrolizumab Combined With Chemotherapy)

Gut Microbiota; NSCLC · Gut Microbiota

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3

pembrolizumab (Keytruda, Pembrolizumab Immunotherapy)

Non-Small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer · Non-Small Cell Lung Cancer

임상시험 1상태 DISCONTINUED

#MetastaticNSCLC#Antibody#Phase3#항체#면역항체+2

pembrolizumab (Keytruda, Pembrolizumab after randomization)

Metastatic NSCLC · Metastatic NSCLC

효능 ORR 31.9%임상시험 1상태 RECRUITING

#Non-small-cellLungCancer#Antibody#Phase3#항체#면역항체+2

pembrolizumab (Keytruda, Pembrolizumab and Chemotherapy drugs)

Non-small-cell Lung Cancer · Non-small-cell Lung Cancer

효능 ORR 62.1%임상시험 1상태 RECRUITING

#MetastaticNSCLC#Antibody#Phase3#항체#면역항체+2

pembrolizumab (Keytruda, Pembrolizumab before randomization)

Metastatic NSCLC · Metastatic NSCLC

효능 ORR 34%임상시험 1상태 RECRUITING

#Melanoma#Antibody#Phase2#항체#면역항체+3

pembrolizumab (Keytruda, Pembrolizumab plus Bevacizumab)

Melanoma; Non-small Cell Lung Cancer · Melanoma

효능 ORR 56.3%임상시험 1상태 ACTIVE

#Non-smallCellLungCancer#Antibody#Phase3#항체#면역항체+2

pembrolizumab (Keytruda, Pembrolizumab, Sintilimab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#EGFR#Antibody#Phase2#항체#면역항체+4

pembrolizumab (Keytruda, Pembrolizumab, pemetrexed, platinum)

Non Small Cell Lung Cancer; Immune Checkpoint Inhibitor · EGFR

#SmallCellLungCarcinoma#Antibody#Phase3#항체#면역항체+2

pembrolizumab (Keytruda, Pembrolizumab/Vibostolimab Co-Formulation)

Small Cell Lung Carcinoma · Small Cell Lung Carcinoma

효능 ORR 71.7%임상시험 1상태 RECRUITING

AntibodystaleMerus B.V.Phase 2

pembrolizumab (Keytruda, Petosemtamab + Pembrolizumab)

Lung Cancer - Non Small Cell Squamous; Lung Cancer - Non Small Cell Non-Squamous · Lung Cancer - Non Small Cell Squamous

#LungCancer-NonSmallCellSquamous#Antibody#Phase2#항체#면역항체+3